Currently browsing: Items authored or edited by Maryam Latarani

Latarani, Maryam; Pucci, Perla; Eccleston, Mark; Manzo, Massimiliano; Gangadharannambiar, Priyadarsini; Fischetti, Irene; Alborelli, Ilaria; Mongiardini, Vera; Mahmood, Namra; Colombo, Mario Paolo; Grimaldi, Benedetto; Rigas, Sushila; Akamatsu, Shusuke; Hawkes, Cheryl; Wang, Yuzhuo; Jachetti, Elena and Crea, Francesco (2025). EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines. Epigenomics, 17(3) pp. 145–154.

• Download Published Version (PDF / 4MB)

Latarani, Maryam (2023). EZH2 as a therapeutic target for aggressive prostate cancer. Master of Philosophy (MPhil) thesis The Open University.

• Download Final Version (PDF / 4MB)

Salani, Francesca; Latarani, Maryam; Casadei-Gardini, Andrea; Gangadharannambiar, Priyadarsini; Fornaro, Lorenzo; Vivaldi, Caterina; Pecora, Irene; Massa, Valentina; Marisi, Giorgia; Canale, Matteo; Ulivi, Paola; Scartozzi, Mario; Eccleston, Mark; Masi, Gianluca and Crea, Francesco (2022). Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib. Epigenomics, 14(9) pp. 507–517.

• Download Published Version (PDF / 2MB)

Latarani, Maryam; Pucci, Perla; Roig-Carles, David; Eccleston, Mark; Xue, Hui; Hawkes, Cheryl; Rigas, Sushila; Wang, Yuzhuo and Crea, Francesco (2020). EZH2 as a therapeutic target for aggressive prostate cancer. In: Crick Cancer Research Symposium, iPoster, 5-6 Oct 2020, The Francis Crick Institute and Virtual.

Kang, Ning; Eccleston, Mark; Clermont, Pier-Luc; Latarani, Maryam; Male, David Kingsley; Wang, Yuzhuo and Crea, Francesco (2020). EZH2 inhibition: a promising strategy to prevent cancer immune editing. Epigenomics, 12(16)

• Download Published Version (PDF / 1MB)